Just as Obiter was frustrated by Savant's reluctance to throw itself behind 18-MC back in 2014, it appears that both Obiter and Savant—or, Scott Freeman and Chad Boulanger, at least—are today frustrated at MindMed's unwillingness to back the drug. There's plenty of skin in the game for FCM, too… Jake Freeman told Psychedelic Alpha that all three members of FCM have shares locked up in Savant, with the total in excess of 8 million shares. It's unclear whether FCM's stunt will remain just that, or whether it will progress into a fully-fledged shareholder activism campaign. "Potentially, we are prepared to launch a full activity campaign to change management's strategic direction", FCM's Jake Freeman said. Editor's note: today, the day after shelving its potential opioid use disorder treatment (18-MC), MindMed announced it has appointed Roger Crystal to its Board.